Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 9/20 | 0.44 |
| ▸ | HTR2B | P41595 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CLPP | Q16740 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623121 | 0.86 | KMT2A (0.49) | MEN1KMT2AC5AR1SIGMAR1HTR2C | |
| SCHEMBL1621143 | 0.85 | C5AR1 (0.47) | MEN1KMT2AC5AR1SIGMAR1HTR2C | |
| SCHEMBL1622308 | 0.83 | HTR2C (0.64) | MEN1KMT2AC5AR1SIGMAR1HTR2C | |
| SCHEMBL1622535 | 0.83 | HTR2A (0.50) | MEN1KMT2AC5AR1SIGMAR1HTR2C | |
| SCHEMBL1622745 | 0.82 | SIGMAR1 (0.52) | MEN1KMT2AC5AR1SIGMAR1HTR2C | |
| SCHEMBL1623057 | 0.80 | LMNA (0.52) | MEN1KMT2AC5AR1SIGMAR1HTR2C | |
| SCHEMBL1622463 | 0.79 | C5AR1 (0.42) | MEN1KMT2AC5AR1SIGMAR1HTR2C | |
| SCHEMBL1622832 | 0.78 | CLPP (0.47) | MEN1KMT2AC5AR1SIGMAR1HTR2C | |
| SCHEMBL4976746 | 0.78 | SIGMAR1 (0.47) | MEN1KMT2AC5AR1SIGMAR1NPC1 | |
| SCHEMBL1623038 | 0.78 | CLPP (0.49) | MEN1KMT2AC5AR1SIGMAR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928099-B2 | Pyrimido [4,5-D] azepine derivatives as 5-HT2c agonists | PFIZER INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | ANDREWS MARK | 2010-05-06 | — | — | US | disclosed |
| EP-2139896-A1 | PYRIMIDO [4, 5-D]AZEPINE DERIVATIVES AS 5-HT2C AGONISTS | Pfizer Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008117169-A1 | PYRIMIDO [4, 5-D] AZEPINE DERIVATIVES AS 5-HT2C AGONISTS | PFIZER LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113422-A1 | Pyrimido [4,5-D] Azepine Derivatives As 5-HT2C Agonists | HTR2C, HTR2A, HTR5A | MEN1 1573/4885KMT2A 1526/4885C5AR1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.